Knights of Columbus Asset Advisors LLC Has $2.90 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Knights of Columbus Asset Advisors LLC boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 125.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,804 shares of the medical equipment provider's stock after buying an additional 26,059 shares during the period. Knights of Columbus Asset Advisors LLC owned approximately 0.07% of Lantheus worth $2,902,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Macquarie Group Ltd. raised its holdings in Lantheus by 21.7% in the first quarter. Macquarie Group Ltd. now owns 605 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 108 shares during the period. Parkside Financial Bank & Trust raised its holdings in Lantheus by 36.6% in the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 156 shares during the period. RFG Advisory LLC raised its holdings in Lantheus by 4.4% in the third quarter. RFG Advisory LLC now owns 3,940 shares of the medical equipment provider's stock worth $274,000 after purchasing an additional 167 shares during the period. Prosperity Financial Group Inc. raised its holdings in Lantheus by 6.2% in the third quarter. Prosperity Financial Group Inc. now owns 2,967 shares of the medical equipment provider's stock worth $206,000 after purchasing an additional 173 shares during the period. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in Lantheus by 3.1% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 6,217 shares of the medical equipment provider's stock worth $432,000 after purchasing an additional 188 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Mary Anne Heino sold 93,863 shares of the firm's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the sale, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Mary Anne Heino sold 93,863 shares of the firm's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the sale, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business's stock in a transaction dated Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold a total of 94,545 shares of company stock valued at $6,169,936 in the last quarter. Company insiders own 1.50% of the company's stock.

Lantheus Stock Performance

Shares of LNTH traded up $1.48 during midday trading on Friday, reaching $63.81. The stock had a trading volume of 798,463 shares, compared to its average volume of 713,367. The firm has a 50 day simple moving average of $60.81 and a 200-day simple moving average of $62.82. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $100.85. The firm has a market cap of $4.37 billion, a PE ratio of 13.75 and a beta of 0.53. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating analysts' consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The company had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.72 EPS for the current year.

Analysts Set New Price Targets

LNTH has been the topic of several analyst reports. Truist Financial reiterated a "buy" rating and issued a $82.00 target price (up from $80.00) on shares of Lantheus in a report on Monday, February 26th. JMP Securities reissued a "market outperform" rating and set a $100.00 price objective on shares of Lantheus in a research report on Friday, February 23rd. B. Riley increased their price objective on shares of Lantheus from $95.00 to $99.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Saturday, January 13th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $104.71.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.